CLINICAL TRIALS PROFILE FOR BMS-986205

Clinical Trials for BMS-986205

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02658890 ↗	An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread	Active, not recruiting	Bristol-Myers Squibb	Phase 1/Phase 2	The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
NCT02750514 ↗	An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer	Terminated	Bristol-Myers Squibb	Phase 2	The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
NCT02935634 ↗	A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer	Active, not recruiting	Clovis Oncology, Inc.	Phase 2	The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.
NCT02935634 ↗	A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer	Active, not recruiting	Bristol-Myers Squibb	Phase 2	The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.
NCT02996110 ↗	A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma	Recruiting	Bristol-Myers Squibb	Phase 2	The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
NCT03192943 ↗	A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors	Completed	Bristol-Myers Squibb	Phase 1	The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors

Clinical Trial Conditions for BMS-986205

Condition Name

Condition Name
Intervention	Trials
Advanced Cancer	7
Healthy Volunteers	3
Bladder Cancer	2
Melanoma	2

Condition MeSH

Condition MeSH
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	3
Urinary Bladder Neoplasms	2
Melanoma	2
Neoplasms	2

Clinical Trial Locations for BMS-986205

Trials by Country

Trials by Country
Location	Trials
United States	149
Australia	27
Canada	26
Japan	21
Brazil	17

Trials by US State

Trials by US State
Location	Trials
Texas	10
California	10
Pennsylvania	8
Maryland	8
Tennessee	7

Clinical Trial Progress for BMS-986205

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	6
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	9
Recruiting	6
Active, not recruiting	4

Clinical Trial Sponsors for BMS-986205

Sponsor Name

Sponsor Name
Sponsor	Trials
Bristol-Myers Squibb	22
National Cancer Institute (NCI)	2
Edward Kim	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	23
Other	4
NIH	2